These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34882581)

  • 1. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.
    Ogino H; Taylor JW; Nejo T; Gibson D; Watchmaker PB; Okada K; Saijo A; Tedesco MR; Shai A; Wong CM; Rabbitt JE; Olin MR; Moertel CL; Nishioka Y; Salazar AM; Molinaro AM; Phillips JJ; Butowski NA; Clarke JL; Oberheim Bush NA; Hervey-Jumper SL; Theodosopoulos P; Chang SM; Berger MS; Okada H
    J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 34882581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
    Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
    Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
    Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM
    Nat Commun; 2024 May; 15(1):3882. PubMed ID: 38719809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.
    Okada H; Butterfield LH; Hamilton RL; Hoji A; Sakaki M; Ahn BJ; Kohanbash G; Drappatz J; Engh J; Amankulor N; Lively MO; Chan MD; Salazar AM; Shaw EG; Potter DM; Lieberman FS
    Clin Cancer Res; 2015 Jan; 21(2):286-94. PubMed ID: 25424847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
    Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
    Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.
    Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H
    Neuro Oncol; 2016 Aug; 18(8):1157-68. PubMed ID: 26984745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
    Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS
    J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
    Sabbatini P; Tsuji T; Ferran L; Ritter E; Sedrak C; Tuballes K; Jungbluth AA; Ritter G; Aghajanian C; Bell-McGuinn K; Hensley ML; Konner J; Tew W; Spriggs DR; Hoffman EW; Venhaus R; Pan L; Salazar AM; Diefenbach CM; Old LJ; Gnjatic S
    Clin Cancer Res; 2012 Dec; 18(23):6497-508. PubMed ID: 23032745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.
    Tsuji T; Sabbatini P; Jungbluth AA; Ritter E; Pan L; Ritter G; Ferran L; Spriggs D; Salazar AM; Gnjatic S
    Cancer Immunol Res; 2013 Nov; 1(5):340-50. PubMed ID: 24777970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas.
    Müller S; Agnihotri S; Shoger KE; Myers MI; Smith N; Chaparala S; Villanueva CR; Chattopadhyay A; Lee AV; Butterfield LH; Diaz A; Okada H; Pollack IF; Kohanbash G
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.
    Mehrotra S; Britten CD; Chin S; Garrett-Mayer E; Cloud CA; Li M; Scurti G; Salem ML; Nelson MH; Thomas MB; Paulos CM; Salazar AM; Nishimura MI; Rubinstein MP; Li Z; Cole DJ
    J Hematol Oncol; 2017 Apr; 10(1):82. PubMed ID: 28388966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
    Saijo A; Ogino H; Butowski NA; Tedesco MR; Gibson D; Watchmaker PB; Okada K; Wang AS; Shai A; Salazar AM; Molinaro AM; Rabbitt JE; Shahin M; Perry A; Clarke JL; Taylor JW; Daras M; Oberheim Bush NA; Hervey-Jumper SL; Phillips JJ; Chang SM; Hilf N; Mayer-Mokler A; Keler T; Berger MS; Okada H
    Neuro Oncol; 2024 Feb; 26(2):335-347. PubMed ID: 37758193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
    Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
    J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
    Slingluff CL; Petroni GR; Chianese-Bullock KA; Wages NA; Olson WC; Smith KT; Haden K; Dengel LT; Dickinson A; Reed C; Gaughan EM; Grosh WW; Kaur V; Varhegyi N; Smolkin M; Galeassi NV; Deacon D; Hall EH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.
    Zhu X; Fallert-Junecko BA; Fujita M; Ueda R; Kohanbash G; Kastenhuber ER; McDonald HA; Liu Y; Kalinski P; Reinhart TA; Salazar AM; Okada H
    Cancer Immunol Immunother; 2010 Sep; 59(9):1401-9. PubMed ID: 20549206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
    Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL
    J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.
    Rodríguez-Ruiz ME; Perez-Gracia JL; Rodríguez I; Alfaro C; Oñate C; Pérez G; Gil-Bazo I; Benito A; Inogés S; López-Diaz de Cerio A; Ponz-Sarvise M; Resano L; Berraondo P; Barbés B; Martin-Algarra S; Gúrpide A; Sanmamed MF; de Andrea C; Salazar AM; Melero I
    Ann Oncol; 2018 May; 29(5):1312-1319. PubMed ID: 29554212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.
    Kyi C; Roudko V; Sabado R; Saenger Y; Loging W; Mandeli J; Thin TH; Lehrer D; Donovan M; Posner M; Misiukiewicz K; Greenbaum B; Salazar A; Friedlander P; Bhardwaj N
    Clin Cancer Res; 2018 Oct; 24(20):4937-4948. PubMed ID: 29950349
    [No Abstract]   [Full Text] [Related]  

  • 19. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
    Mueller S; Taitt JM; Villanueva-Meyer JE; Bonner ER; Nejo T; Lulla RR; Goldman S; Banerjee A; Chi SN; Whipple NS; Crawford JR; Gauvain K; Nazemi KJ; Watchmaker PB; Almeida ND; Okada K; Salazar AM; Gilbert RD; Nazarian J; Molinaro AM; Butterfield LH; Prados MD; Okada H
    J Clin Invest; 2020 Dec; 130(12):6325-6337. PubMed ID: 32817593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial.
    Nakajima M; Hazama S; Tamada K; Udaka K; Kouki Y; Uematsu T; Arima H; Saito A; Doi S; Matsui H; Shindo Y; Matsukuma S; Kanekiyo S; Tokumitsu Y; Tomochika S; Iida M; Yoshida S; Nakagami Y; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Ueno T; Nagano H
    Cancer Immunol Immunother; 2020 Aug; 69(8):1651-1662. PubMed ID: 32219501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.